Bony tumor treated with Tranexamic acid (TXA) for Sarcoma

Phase-Based Progress Estimates
3
Effectiveness
3
Safety
Sarcoma+2 More
Tranexamic Acid (TXA) - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test whether a drug called tranexamic acid reduces blood loss and the need for transfusions in patients undergoing surgery for musculoskeletal cancer.

Eligible Conditions
  • Sarcoma
  • Soft Tissue Sarcoma (STS)
  • Musculoskeletal Cancers

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: Postoperative days 1-3

Postoperative days 1-3
Blood transfusion rates
Perioperative blood loss
Surgical drain output

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

4 Treatment Groups

Soft tissue sarcoma treated without TXA
1 of 4
Bony tumor treated without TXA
1 of 4
Bony tumor treated with Tranexamic acid (TXA)
1 of 4
Soft tissue sarcoma treated with Tranexamic Acid (TXA)
1 of 4

Active Control

90 Total Participants · 4 Treatment Groups

Primary Treatment: Bony tumor treated with Tranexamic acid (TXA) · No Placebo Group · Phase 4

Soft tissue sarcoma treated without TXANoIntervention Group · 1 Intervention: Soft tissue sarcoma treated without TXA · Intervention Types:
Bony tumor treated without TXANoIntervention Group · 1 Intervention: Bony tumor treated without TXA · Intervention Types:
Bony tumor treated with Tranexamic acid (TXA)
Drug
ActiveComparator Group · 1 Intervention: Tranexamic Acid (TXA) · Intervention Types: Drug
Soft tissue sarcoma treated with Tranexamic Acid (TXA)
Drug
ActiveComparator Group · 1 Intervention: Tranexamic Acid (TXA) · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: postoperative days 1-3

Who is running the clinical trial?

University of Kansas Medical CenterLead Sponsor
397 Previous Clinical Trials
158,103 Total Patients Enrolled
Kyle Sweeney, MDPrincipal Investigator - University of Kansas Medical Center
University of Kansas Medical Center

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Patients undergoing wide resection of a malignant bony tumor of the lower extremity with endoprosthetic reconstruction.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: November 21st, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.